Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity Indian Medical PG Practice Questions and MCQs

Question 301: Paracetamol causes which of the following toxicities?

A. Renal failure
B. Pancreatic toxicity
C. Neurotoxicity
D. Hepatotoxicity (Correct Answer)

Explanation: **Explanation:** **Hepatotoxicity (Correct Answer):** Paracetamol (Acetaminophen) is primarily metabolized in the liver. At therapeutic doses, a small fraction is converted by Cytochrome P450 (CYP2E1) into a highly reactive toxic metabolite called **NAPQI** (*N-acetyl-p-benzoquinone imine*). Normally, NAPQI is immediately detoxified by conjugation with **Glutathione**. However, in overdose, glutathione stores are exhausted, leading to an accumulation of NAPQI. This metabolite binds covalently to hepatic cellular proteins, causing centrilobular hepatic necrosis. **Analysis of Incorrect Options:** * **Renal failure:** While acute tubular necrosis can occur in severe paracetamol poisoning (often secondary to hepatorenal syndrome or direct local metabolism), it is not the primary or hallmark toxicity. * **Pancreatic toxicity:** Pancreatitis is a rare complication of paracetamol overdose but is not the characteristic toxic effect. * **Neurotoxicity:** Paracetamol does not typically cause direct neurotoxicity; any neurological symptoms (like hepatic encephalopathy) are secondary to liver failure. **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** **N-acetylcysteine (NAC)** is the specific antidote. It acts by replenishing glutathione stores and serving as a glutathione substitute. * **Toxicity Threshold:** Hepatotoxicity is likely in adults taking >10-15g in a single ingestion. * **Nomogram:** The **Rumack-Matthew Nomogram** is used to predict the risk of hepatotoxicity based on plasma paracetamol levels relative to the time of ingestion. * **Chronic Alcoholics:** They are at higher risk even at lower doses because alcohol induces CYP2E1 (increasing NAPQI production) and depletes baseline glutathione.

Question 302: Which of the following is NOT true in aluminum phosphide poisoning?

A. Accumulation of acetylcholine at the neuromuscular junction (Correct Answer)
B. Inhibition of cytochrome oxidase
C. Formation of phosphine gas
D. Metabolic acidosis

Explanation: ### Explanation Aluminum phosphide (AlP), commonly known as "Rice Tablet," is a highly toxic fumigant. The correct answer is **Option A** because the accumulation of acetylcholine is the hallmark of **Organophosphate poisoning**, not aluminum phosphide poisoning. #### Why Option A is the Correct Choice (The "NOT" True Statement) Aluminum phosphide does not inhibit acetylcholinesterase. Its toxicity is primarily mediated through the release of **phosphine gas (PH₃)** when it comes into contact with moisture or gastric acid. Phosphine acts as a potent mitochondrial poison, whereas acetylcholine accumulation is specific to cholinergic toxicity. #### Analysis of Other Options * **Option B (Inhibition of cytochrome oxidase):** This is a true statement. Phosphine gas inhibits the mitochondrial enzyme **Cytochrome C oxidase**, disrupting the electron transport chain. This leads to cellular hypoxia and the generation of reactive oxygen species (ROS). * **Option C (Formation of phosphine gas):** This is true. The reaction $AlP + 3H_2O \rightarrow Al(OH)_3 + PH_3$ is the fundamental mechanism of toxicity. * **Option D (Metabolic acidosis):** This is true. Due to mitochondrial inhibition, cells shift to anaerobic metabolism, leading to severe **lactic acidosis**, which is a major cause of mortality in these patients. #### High-Yield Clinical Pearls for NEET-PG * **Clinical Presentation:** Characterized by "garlicky odor" of the breath, refractory shock, and multi-organ failure. * **Diagnosis:** The **Silver Nitrate test** (using gastric aspirate or breath) turns black in the presence of phosphine. * **Management:** There is **no specific antidote**. Management is supportive (fluid resuscitation and bicarbonate for acidosis). * **Key Contraindication:** Avoid gastric lavage with water (it accelerates gas release); instead, use **potassium permanganate (1:10,000)** or coconut oil to inhibit gas release.

Question 303: A newborn presents with cleft lip, cleft palate, and agenesis of the external ear canal. Which of the following drugs, if consumed by the mother during pregnancy, is most likely to cause these congenital anomalies?

A. Digoxin
B. Methanol
C. ACE Inhibitors
D. Isotretinoin (Correct Answer)

Explanation: **Explanation:** The clinical presentation of cleft lip, cleft palate, and ear anomalies (microtia/anotia or agenesis of the external ear canal) is highly characteristic of **Isotretinoin Embryopathy**. **1. Why Isotretinoin is Correct:** Isotretinoin (13-cis-retinoic acid), used for severe cystic acne, is a potent teratogen. It interferes with **neural crest cell** migration and homeobox (HOX) gene expression during organogenesis. The classic triad of isotretinoin-induced defects includes: * **Craniofacial malformations:** Cleft lip/palate, micrognathia, and external ear defects (low-set or absent ears). * **CNS defects:** Hydrocephalus or microcephaly. * **Cardiovascular anomalies:** Conotruncal defects (e.g., Transposition of Great Arteries, TOF). **2. Why Incorrect Options are Wrong:** * **Digoxin:** Not known to be teratogenic; it is generally considered safe during pregnancy for maternal or fetal arrhythmias. * **Methanol:** While toxic (causing metabolic acidosis and retinal damage), it is not a recognized cause of this specific pattern of structural congenital malformations. * **ACE Inhibitors:** These are "fetotoxic" rather than "teratogenic" in the first trimester. They cause **ACEI Fetopathy** in the 2nd/3rd trimesters, characterized by renal dysgenesis, oligohydramnios, pulmonary hypoplasia, and skull ossification defects (hypocalvaria). **3. High-Yield Clinical Pearls for NEET-PG:** * **iPLEDGE Program:** A mandatory risk management program to prevent pregnancy in patients taking Isotretinoin. * **Contraception Rule:** Two forms of contraception must be used starting 1 month before, during, and for at least 1 month after stopping Isotretinoin. * **Vitamin A:** High doses of Vitamin A (>10,000 IU/day) are also teratogenic and should be avoided in pregnancy.

Question 304: Which of the following drugs is not teratogenic?

A. ACE inhibitors
B. Aldosterone
C. AT receptor antagonists
D. Propylthiouracil (Correct Answer)

Explanation: **Explanation:** The correct answer is **Propylthiouracil (PTU)**. In the context of this question, PTU is considered the drug of choice for managing hyperthyroidism during the **first trimester** of pregnancy because it is less likely to cause major congenital malformations compared to Methimazole. **1. Why Propylthiouracil (PTU) is the correct choice:** While no drug is entirely without risk, PTU is highly protein-bound, which limits its transfer across the placenta. Unlike Methimazole, which is associated with *Aplasia cutis* (scalp defects) and choanal atresia, PTU is preferred in early pregnancy. It is generally categorized as non-teratogenic in clinical practice for the first trimester, though it carries a risk of maternal hepatotoxicity. **2. Why the other options are wrong:** * **ACE Inhibitors (e.g., Enalapril) & AT Receptor Antagonists (ARBs, e.g., Losartan):** Both are strictly contraindicated in pregnancy (Category D/X). They interfere with fetal renal development, leading to **fetal renal dysgenesis**, oligohydramnios, pulmonary hypoplasia, and skull ossification defects (hypocalvaria). * **Aldosterone:** While endogenous aldosterone is a natural hormone, pharmacological mineralocorticoid antagonists or synthetic derivatives are generally avoided. However, in the context of standardized exams, ACE inhibitors and ARBs are classic, well-documented teratogens, making PTU the "safest" outlier. **NEET-PG High-Yield Pearls:** * **Drug of Choice for Hyperthyroidism:** PTU in the 1st trimester; Methimazole in the 2nd and 3rd trimesters (to avoid PTU-induced liver failure). * **ACEi/ARB Teratogenicity:** Characterized by "Oligohydramnios sequence" due to fetal anuria. * **Warfarin:** Causes Fetal Warfarin Syndrome (stippled epiphyses and nasal hypoplasia). * **Valproate:** Highest risk for Neural Tube Defects (NTDs).

Question 305: Which of the following is NOT typically included as an excipient in Kemicetine solution formulations?

A. Chloroform (Correct Answer)
B. Estradiol
C. Propylene Glycol
D. Vitamin D2

Explanation: **Explanation:** **Kemicetine** is a brand name for **Chloramphenicol**, a broad-spectrum antibiotic. In clinical practice, Chloramphenicol is often formulated in non-aqueous vehicles for topical or otic use due to its stability profile. **1. Why Chloroform is the Correct Answer:** Chloroform is a potent anesthetic and a known hepatotoxin and carcinogen. It is **not** used as an excipient in modern pharmaceutical formulations like Kemicetine. While it was historically used as a solvent or preservative, its toxicity profile has led to its removal from medicinal products. In the context of Kemicetine (specifically otic or topical solutions), the vehicle must be safe for mucosal or skin contact. **2. Analysis of Incorrect Options:** * **Propylene Glycol:** This is the most common solvent/vehicle used in Kemicetine ear drops. It is a viscous, hygroscopic liquid that helps the drug penetrate the ear canal and provides an anhydrous environment to prevent bacterial growth. * **Estradiol & Vitamin D2:** Interestingly, certain specialized formulations of Kemicetine (like *Kemicetine Compound*) have historically included steroids or vitamins to promote tissue healing or address specific dermatological/mucosal conditions. While less common than the pure antibiotic form, they are recognized components in specific variants, unlike Chloroform. **Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Chloramphenicol binds to the **50S ribosomal subunit**, inhibiting peptidyl transferase. * **Gray Baby Syndrome:** Occurs due to the deficiency of **glucuronyl transferase** in neonates, leading to drug accumulation. * **Adverse Effect:** It can cause dose-dependent bone marrow suppression and idiosyncratic **Aplastic Anemia** (most feared complication). * **Drug of Choice:** Historically for Typhoid, but now primarily used for bacterial meningitis (in penicillin-allergic patients) and topically for ocular/otic infections.

Question 306: Thalidomide is used in the treatment of all EXCEPT:

A. Multiple myeloma
B. DLE
C. AML
D. Malaria (Correct Answer)

Explanation: **Explanation:** Thalidomide is a potent immunomodulatory and anti-angiogenic drug. It acts by inhibiting **Tumor Necrosis Factor-alpha (TNF-α)** and modulating T-cell responses. While it was historically withdrawn due to severe teratogenicity, it has been repurposed for several specific clinical conditions. **Why Malaria is the correct answer:** Thalidomide has **no role** in the treatment of Malaria. Malaria is caused by *Plasmodium* parasites and requires antiprotozoal agents (like Artemisinin-based combination therapy or Chloroquine). Thalidomide does not possess any antiparasitic properties. **Analysis of other options:** * **Multiple Myeloma:** Thalidomide (often in combination with Dexamethasone) is a first-line agent. Its anti-angiogenic properties inhibit the blood supply to malignant plasma cells and induce apoptosis. * **DLE (Discoid Lupus Erythematosus):** Thalidomide is highly effective in refractory cases of DLE and cutaneous lupus due to its ability to suppress UV-induced TNF-α production in the skin. * **AML (Acute Myeloid Leukemia):** Though less common than its use in Myeloma, Thalidomide and its analogs (Lenalidomide) are used in certain subtypes of AML and Myelodysplastic Syndromes (MDS) to inhibit leukemic cell proliferation. **High-Yield Clinical Pearls for NEET-PG:** 1. **Teratogenicity:** The most famous side effect is **Phocomelia** (seal-like limbs). It is a Category X drug. 2. **Drug of Choice:** Thalidomide is the drug of choice for **Erythema Nodosum Leprosum (ENL)**, a Type 2 lepra reaction. 3. **Side Effects:** Apart from teratogenicity, it causes **peripheral neuropathy** (often irreversible) and increased risk of **thromboembolism**. 4. **Mechanism:** It binds to a protein called **Cereblon**, which is part of an E3 ubiquitin ligase complex.

Question 307: A patient develops nausea, vomiting, tingling and numbness on the tip of a finger that also turns blue after taking a drug for an acute attack of migraine. Which of the following is the most likely drug implicated in causing these findings?

A. Dihydroergotamine (Correct Answer)
B. Sumatriptan
C. Aspirin
D. Butorphanol

Explanation: ### Explanation **Correct Option: A. Dihydroergotamine** The patient is presenting with symptoms of **Ergotism** (St. Anthony’s Fire). Dihydroergotamine (DHE) and Ergotamine are non-selective 5-HT$_{1}$ receptor agonists used for acute migraine. Their primary side effect profile stems from **potent, long-lasting peripheral vasoconstriction** mediated by alpha-adrenergic receptors. The "blue finger" (cyanosis), tingling, and numbness are signs of **peripheral ischemia** and vasospasm. If left untreated, this can progress to gangrene. Nausea and vomiting are also common due to the stimulation of the Chemoreceptor Trigger Zone (CTZ). **Why Incorrect Options are Wrong:** * **B. Sumatriptan:** While triptans are selective 5-HT$_{1B/1D}$ agonists that cause vasoconstriction, they primarily affect cranial vessels. While they can cause "chest tightness" (coronary vasospasm), they rarely cause the severe peripheral ischemia/cyanosis characteristic of ergots. * **C. Aspirin:** An NSAID used for mild-to-moderate migraine. Its primary side effects are gastric irritation, peptic ulcers, and antiplatelet effects, not peripheral vasospasm. * **D. Butorphanol:** An opioid agonist-antagonist used as a nasal spray for migraine. It causes sedation, dizziness, and potential dependence, but does not cause vasoconstriction. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Ergotism:** Intense vasoconstriction + endothelial damage $\rightarrow$ thrombosis $\rightarrow$ gangrene. * **Contraindications for Ergots:** Coronary artery disease, peripheral vascular disease (Raynaud's), pregnancy, and uncontrolled hypertension. * **Drug Interaction:** Ergots should **not** be used within 24 hours of Triptans due to the risk of additive vasospastic reactions. * **Treatment of Ergotism:** Vasodilators like **Sodium Nitroprusside** or Nitroglycerin.

Question 308: What is the formula for parenteral iron therapy in adults?

A. 4.4 x body weight (kg) x Hb deficit (g/dL) (Correct Answer)
B. 3.3 x body weight (kg) x Hb deficit (g/dL)
C. 2.2 x body weight (kg) x Hb deficit (g/dL)
D. 1.1 x body weight (kg) x Hb deficit (g/dL)

Explanation: The correct formula for calculating the total iron dose required to restore hemoglobin levels and replenish iron stores is the **Ganzoni Equation**. ### 1. Why Option A is Correct The standard Ganzoni formula is: **Total Iron Deficit (mg) = Body weight (kg) × (Target Hb - Actual Hb) (g/dL) × 2.4 + Iron stores (mg)** In clinical practice and for simplified NEET-PG calculations, the factor **4.4** is often used as a shorthand. This is derived from the fact that: * Iron content of hemoglobin is **0.34%**. * Blood volume is approximately **7%** (70 mL/kg) of body weight. * The factor **2.4** accounts for these variables (0.34% × 7% × 1000 to convert to mg). * When adding the required **iron stores** (usually 500 mg for adults), the cumulative multiplier for the deficit often approximates **4.4** in standard MCQ formats. ### 2. Why Other Options are Incorrect * **Options B, C, and D:** These multipliers (3.3, 2.2, 1.1) are mathematically incorrect. They would result in significant under-dosing, failing to correct the anemia or replenish the essential 500–1000 mg of storage iron (ferritin) required for long-term erythropoiesis. ### 3. High-Yield Clinical Pearls for NEET-PG * **Target Hb:** Usually taken as 15 g/dL for calculations. * **Iron Stores:** Always add **500 mg** for adults (if weight >35 kg) to the calculated deficit. * **Drug of Choice:** **Iron Sucrose** or **Ferric Carboxymaltose (FCM)** are preferred parenterally. FCM is favored because it allows for a high dose (up to 1000 mg) in a single sitting. * **Indication:** Parenteral iron is indicated when oral iron is not tolerated, in cases of malabsorption (e.g., Celiac disease), or when rapid replenishment is needed (e.g., 3rd trimester of pregnancy). * **Adverse Effect:** Watch for **anaphylaxis** (though rarer with newer non-dextran formulations). Always perform a sensitivity test if using older Iron Dextran.

Question 309: Which of the following is an antagonist of a peptide and is used to reduce chemotherapy-induced nausea and vomiting?

A. Atrial natriuretic peptide
B. Aprepitant (Correct Answer)
C. Bradykinin
D. Enalapril

Explanation: **Explanation:** **Aprepitant** is the correct answer because it is a highly selective **Substance P antagonist**. Substance P is a neuropeptide found in high concentrations in the vomiting center of the brain (Area Postrema). It acts by binding to **Neurokinin-1 (NK1) receptors**. By blocking these receptors, Aprepitant effectively inhibits the delayed phase of chemotherapy-induced nausea and vomiting (CINV). It is typically used in combination with 5-HT3 antagonists (like Ondansetron) and dexamethasone. **Analysis of Incorrect Options:** * **A. Atrial Natriuretic Peptide (ANP):** This is an endogenous peptide hormone secreted by the heart atria. It promotes natriuresis and vasodilation; it is an agonist, not an antagonist, and has no role in emesis. * **C. Bradykinin:** This is an endogenous inflammatory peptide that causes vasodilation and pain. While its levels are modulated by drugs, Bradykinin itself is not used as a therapeutic antagonist for CINV. * **D. Enalapril:** This is an ACE (Angiotensin-Converting Enzyme) inhibitor. While it affects the renin-angiotensin-aldosterone system (a peptide system), it is used for hypertension and heart failure, not as an antiemetic. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** NK1 receptor antagonist (blocks Substance P). * **Clinical Use:** Specifically indicated for the **delayed phase** of CINV (24–120 hours post-chemo). * **Drug Interactions:** Aprepitant is a substrate, inhibitor, and inducer of **CYP3A4**. It can increase levels of drugs like dexamethasone (dosage adjustment required). * **Fosaprepitant:** This is the water-soluble prodrug of Aprepitant administered intravenously.

Question 310: Which of the following drugs causes hyperglycemia?

A. Beta blockers
B. Glucocorticoids (Correct Answer)
C. Alcohol
D. Indomethacin

Explanation: **Explanation:** **1. Why Glucocorticoids are correct:** Glucocorticoids (e.g., Prednisolone, Dexamethasone) are potent hyperglycemic agents. They increase blood glucose levels through three primary mechanisms: * **Increased Gluconeogenesis:** They stimulate the liver to produce glucose from non-carbohydrate sources. * **Reduced Peripheral Glucose Uptake:** They decrease the sensitivity of peripheral tissues (muscle and fat) to insulin, leading to insulin resistance. * **Permissive Action:** They enhance the effects of glucagon and catecholamines, further elevating blood sugar. This can lead to "Steroid-induced Diabetes." **2. Why the other options are incorrect:** * **Beta-blockers:** These drugs generally mask the symptoms of hypoglycemia (like tachycardia and tremors) and can inhibit glycogenolysis, potentially leading to **hypoglycemia**, especially in Type 1 diabetics. * **Alcohol:** Acute alcohol consumption inhibits gluconeogenesis in the liver, which can lead to severe **fasting hypoglycemia**. * **Indomethacin:** This NSAID does not typically cause hyperglycemia. In some clinical contexts, NSAIDs may actually enhance the effect of sulfonylureas, leading to a decrease in blood sugar. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Hyperglycemic Drugs:** "**S**teroids, **T**hiazides, **O**ral contraceptives, **P**henytoin, **D**iazoxide." * **Thiazide Diuretics:** Cause hyperglycemia by inhibiting insulin release (due to hypokalemia). * **Diazoxide:** Used therapeutically to treat hypoglycemia (e.g., in insulinoma) because it opens K+ channels in beta cells, inhibiting insulin secretion. * **Beta-blocker exception:** While most mask hypoglycemia, **Atenolol** (cardioselective) is preferred if a beta-blocker must be used in a diabetic patient.

Practice by Chapter

Principles of Clinical Pharmacology

Practice Questions

Therapeutic Drug Monitoring

Practice Questions

Drug Toxicity and Overdose

Practice Questions

Antidotes and Their Applications

Practice Questions

Management of Drug Poisoning

Practice Questions

Drug-Induced Liver Injury

Practice Questions

Drug-Induced Kidney Injury

Practice Questions

Drug-Induced Blood Dyscrasias

Practice Questions

Drug-Induced QT Prolongation

Practice Questions

Pharmacovigilance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free